Menu
SOPHiA GENETICS is excited to be a part of the Association for Molecular Pathology (AMP) 2024 Europe Congress held in Madrid, Spain from June 24th - 26th.
You will have the chance to chat with our experts at booth #12 and demo the universal SOPHiA DDM™ Platform.
Join us for our talk "From DNA to insights: Uncovering the overlooked with innovative NGS technology for MRD assessment" presented by Jose Maria Belloso, PhD, Global Product Manager – HemOnc, SOPHiA GENETICS and Silvia Salmoiraghi, PhD, Ultra-specialist Laboratory of Clinical Pathology-Hematology, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
During our presentation, the following topics will be discussed:
Date: June 25th, 2024
Time: 9:45 - 10:45
While on site, make sure to check out our poster:
Fine-Tuning Sensitivity: Establishing an Optimal Framework for Measurable Residual Disease Detection in Acute Myeloid Leukemia at 0.01%
R. Kempfer, J. Bieler, Y. Liu, A. Willig, S. Kubik, Z. Xu
We look forward to seeing you there!
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
